Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Ionis Pharmaceuticals

A Drug That Could Functionally Cure Hepatitis B Achieved That Goal in 1 in 5 Patients in Two Major Phase 3 Trials

Phase 3 B-Well trials published in NEJM showed bepirovirsen achieved functional cure in 20% of chronic hepatitis B patients — the first phase 3 evidence of this kind for the disease.

Medical Daily

The Phase 3 Failure That Sent Biotech Winners and Losers in Opposite Directions

Wainua missed its Phase 3 endpoint, hitting Ionis Pharmaceuticals hard while AstraZeneca absorbed the blow easily, boosting rivals BridgeBio, Pfizer and Alnylam Pharmaceuticals.

MarketBeat

Strength in Chipmakers Boosts Stock Indexes

The S&P 500 Index ($SPX ) (SPY ) today is up +0.48%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is up +0.26%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +1.27%. September E-mini S&P futures (ESU26 ) are up +0.49%, and September E-mini Nasdaq futures...

Barchart

From analysis to the latest developments in health,
read the most diverse news in one place.

Stocks Climb on Strength in Chipmakers

The S&P 500 Index ($SPX ) (SPY ) today is up +0.47%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is up +0.14%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +1.55%. September E-mini S&P futures (ESU26 ) are up +0.47%, and September E-mini Nasdaq futures...

Barchart

Ionis Pharmaceuticals Eyes Big Year With TRYNGOLZA Decision, 5 Phase 3 Readouts

Ionis Pharmaceuticals (NASDAQ:IONS) highlighted a busy slate of regulatory decisions, clinical readouts and partnered programs during a presentation at RBC Capital Markets’ Global Healthcare Conference, with Chief Development Officer Holly Kordasiewicz saying the company is moving from recent launch

MarketBeat

Ionis Pharmaceuticals Touts $3B TRYNGOLZA Opportunity, Pipeline Readouts at Conference

Executives at a healthcare investor event outlined commercial launch plans, pipeline readouts and market-development priorities across several biotechnology franchises, with discussion spanning Ionis Pharmaceuticals (NASDAQ:IONS) products including TRYNGOLZA, DAWNZERA and WAINUA, as well as Neurocri

MarketBeat

When Insider Selling Is a Good Thing: 2 Stocks to Watch

Ionis Pharmaceuticals and Waste Management insiders sell in early 2026, creating buying opportunities in their stocks while analysts raise price targets.

MarketBeat

Read news from The Economist, FT, and more,
with one subscription

Ionis Reports Substantial Drop In Acute Pancreatitis Events With Cholesterol Lowering Drug

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) on Sunday shared results from the pivotal Phase 3 CORE and CORE2 studies of olezarsen for severe hypertriglyceridemia (sHTG), a condition characterized by dangerously high triglyceride (fat) levels.

Benzinga

Ionis Pharmaceuticals Reveals 'Unprecedented Results' From Rare Neurological Disease Trial

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) released topline results on Monday from the pivotal study of zilganersen in children and adults living with Alexander disease (AxD), a rare, progressive, and often fatal neurological condition.

Benzinga

Ionis Pharma's Investigational Drug Shows Promise For Triglyceride And Pancreatitis Reduction

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) on Tuesday released topline results from the pivotal Phase 3 CORE and CORE2 studies of olezarsen for severe hypertriglyceridemia (sHTG).

Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For September 9, 2022

Upgrades

Benzinga

Important Biotech Catalysts For September 7, 2022 - End Of The Day Summary

The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to Pfizer’s (NYSE:PFE) lead drug GBS6 or PF-06760805 for the prevention of invasive GBS disease due to the vaccine serotypes in newborns and young infants by active immunization of their mothers during pregnancy. Pfizer shares traded in a…

Benzinga

Recap of Wednesday's Biotech Catalysts - End of The Day Summary

Benzinga

Ionis Pharmaceuticals Earnings Perspective: Return On Capital Employed

Benzinga Pro data, Ionis Pharmaceuticals (NASDAQ:IONS) reported Q1 sales of $142.00 million. Earnings fell to a loss of $65.17 million, resulting in a 129.01% decrease from last quarter.

Benzinga

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

What 5 Analyst Ratings Have To Say About Ionis Pharmaceuticals

Within the last quarter, Ionis Pharmaceuticals (NASDAQ:IONS) has observed the following analyst ratings:

Benzinga

Recap: Ionis Pharmaceuticals Q1 Earnings

Ionis Pharmaceuticals (NASDAQ:IONS) reported its Q1 earnings results on Wednesday, May 4, 2022 at 08:00 AM. Here's what investors need to know about the announcement.

Benzinga

Expert Ratings For Ionis Pharmaceuticals

Within the last quarter, Ionis Pharmaceuticals (NASDAQ:IONS) has observed the following analyst ratings:

Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For March 1, 2022

Upgrades

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

What 5 Analyst Ratings Have To Say About Ionis Pharmaceuticals

Ionis Pharmaceuticals (NASDAQ:IONS) has observed the following analyst ratings within the last quarter:

Benzinga

BofA Downgrades Ionis After Vupanorsen Setback: Are There Upcoming Catalysts That Can Help The Stock?

Ionis Pharmaceuticals Inc (NASDAQ: IONS) announced on Monday the discontinuation of the Vupanorsen clinical development program. Following this, there are no high-impact catalysts for the next 12 months that could unlock value, according to BofA Securities.

Organisations

From analysis to the latest developments in health,
read the most diverse news in one place.

Topics

Dow Jones Industrial Average

Read news from The Economist, FT, and more,
with one subscription

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.